Abstract Library

#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan

Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ito T, Masui T, Komoto I,

Keywords: GEP-NEN, Guideline, Japan,

#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Masui T

Authors: Masui T, Imamura M, Ito T, Unno M, Okusaka T,

Keywords: registry system, Japan,,

#1645 A Role of TETs and 5-Hydroxymethylcytosine in SI-NETs

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing neoplasms. Identification of patients with worse outcome and of novel potential targets for therapy is important goals. The epigenetic mark 5-hydroxymethylcytosine (5-hmC) is severely reduced in various cancers and was recently found by us to discriminate between parathyroid adenoma and carcinoma. A growth regulatory role of TET1 was also found.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barazeghi E, Prabhawa S, Hellman P, Norlén O, Stålberg P,

Keywords: SI-NET, 5-hydroxymethylcytosine, TETs,

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,

#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms

Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lee L

Authors: Lee L, Ito T, Kawabe K, Otsuka T, Nakamura M,

Keywords: Somatostatin receptor, dopamine receptor, SSTR2, D2R,